<DOC>
	<DOCNO>NCT02535091</DOCNO>
	<brief_summary>This multicenter , open label study assess safety pharmacokinetics YKP3089 adjunctive therapy subject partial onset seizure . Initially , subject take phenytoin phenobarbital enrol follow additional subject take anti-epileptic drug phenytoin phenobarbital investigate long-term safety .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study YKP3089 Adjunctive Therapy Subjects With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female great equal 18 year age time sign informed consent . The upper age limit 70 year inclusive . 2 . Weight least 30 kg 3 . Written inform consent sign subject legal guardian prior enter study accordance ICH GCP guideline . If write informed consent provide legal guardian subject unable , write verbal assent subject must also obtain . In Germany , subject may sign informed consent form accordance ICH guideline . 4 . A diagnosis partial epilepsy accord International League Against Epilepsy 's Classification Epileptic Seizures . Diagnosis establish clinical history electroencephalogram ( EEG ) consistent localization relate epilepsy ; normal interictal EEGs allow provide subject meet diagnosis criterion ( ie , clinical history ) . 5 . Have uncontrolled partial seizure require additional AED therapy despite treat least one AED within approximately last 2 year . 6 . Currently stable antiepileptic treatment regimen : 1 . Subject must receive stable dos 1 3 AEDs least 3 week prior Visit 2 2 . Vagal nerve stimulator ( VNS ) count AED ; however , parameter must remain stable least 4 week prior baseline . The VNS must implant least 5 month prior Visit 1 . 3 . Benzodiazepines take least per week 1 month prior Visit 1 epilepsy , anxiety sleep disorder , count 1 AED must continue unchanged throughout study . Therefore maximum 2 additional approve AEDs allow . 7 . Computed tomography ( CT ) magnetic resonance imaging ( MRI ) scan perform within past 10 year rule progressive cause epilepsy . If CT MRI perform within past 10 year , one must perform prior randomization . 8 . Ability reach subject telephone . 9 . Use acceptable form birth control female subject childbearing potential Exclusion Criteria 1 . History serious druginduced hypersensitivity reaction ( include limit Stevens Johnson syndrome , toxic epidermal necrolysis , drug reaction eosinophilia systemic symptom ) drugrelated rash require hospitalization . 2 . History druginduced rash hypersensitivity reaction . 3 . History first degree relative serious cutaneous druginduced adverse reaction . 4 . History serious systemic disease , include hepatic insufficiency , renal insufficiency , malignant neoplasm , disorder prognosis survival le 3 month , disorder judgment investigator place subject excessive risk participation control trial 5 . Subjects take phenytoin must take phenobarbital primidone ; subject take phenobarbital must take phenytoin primidone 6 . Subjects take concomitant AEDs phenytoin phenobarbital , must take phenytoin phenobarbital primidone 7 . Subjects clinical evidence phenytoin phenobarbital toxicity 8 . A history nonepileptic psychogenic seizures 9 . Presence nonmotor simple partial seizure primary generalized epilepsy 10 . Presence LennoxGastaut syndrome 11 . Scheduled epilepsy surgery within 8 month Visit 1 12 . Subjects implant plan implantation deep brain stimulator 13 . Pregnancy lactation 14 . Any clinically significant laboratory abnormality opinion investigator would exclude subject study 15 . Evidence significant active hepatic disease . Stable elevation liver enzyme , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) due concomitant medication ( ) allow less 3 time upper limit normal ( ULN ) 16 . An active CNS infection , demyelinate disease , degenerative neurologic disease , CNS disease deem progressive course study may confound interpretation study result 17 . Any clinically significant psychiatric illness , psychological , behavioral problem , opinion investigator , would interfere subject 's ability participate study 18 . Presence psychotic disorder and/or unstable recurrent affective disorder evident use antipsychotic ; presence recent history ( within 6 month ) major depressive episode 19 . History alcoholism , drug abuse , drug addiction within past 2 year 20 . Current use felbamate le 18 month continuous exposure 21 . Current recent ( within past year ) use vigabatrin ezogabine . Subjects prior history treatment vigabatrin must documentation show evidence vigabatrin associate clinically significant abnormality visual perimetry test . Subjects prior history treatment ezogabine evidence retinal abnormality funduscopic feature similar see retinal pigment dystrophy . 22 . History status epilepticus within 3 month Visit 1 23 . Screening laboratory investigation demonstrate abnormal renal function 24 . Absolute neutrophil count less 1500/µL 25 . Clinical ECG evidence serious cardiac disease , include ischemic heart disease , uncontrolled heart failure , major arrhythmia , relevant replicate change QT interval ( QTcF le 340 msec great 450 msec male great 470 msec female ) 26 . Platelet count low 80,000/µL subject treat VPA 27 . A `` yes '' answer Question 1 2 CSSRS ( Baseline/Screening version ) Ideation Section past 6 month `` yes '' answer Suicidal Behavior Questions past 2 year . 28 . More 1 lifetime suicide attempt 29 . Participation trial involve investigational product device within 30 day screen ( longer , require local regulation ) 30 . Current use follow medication : clopidogrel , fluvoxamine , amitriptyline , clomipramine , bupropion , methadone , ifosfamide , cyclophosphamide , efavirenz , fosphenytoin , ethotoin , mephenytoin , natural progesterone ( within 1 month Visit 1 ) 31 . History positive antibody/antigen test hepatitis B , hepatitis C , HIV 32 . Presence congenital short QT syndrome 33 . A history previous exposure YKP3089</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>